FY2025 · ended Dec 31, 2025 · Revenue $26.55M, -51.0% YoY · Filed Apr 30, 2026
Celularity Inc. (CELU) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $26.6 million and a net loss of $91.7 million. As of Jun 30, 2026 it held $586,000 in cash and investments and $27.1 million in total debt.
Revenue (TTM)
$18.67M
-58.1% vs year-ago TTM
Net income (TTM)
$-45.86M
+37.8% vs year-ago TTM
Operating cash flow (TTM)
$-8.92M
-251.0% vs year-ago TTM
Free cash flow
$-6.56M
+83.5% vs prior year
EPS (TTM)
$-1.63
+49.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
32.45M
+12.1% vs prior year
Net cash
$-26.47M
as of Jun 30, 2026
Operating margin
-264.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CELU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Florham Park, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1752828
- Former names
- GX Acquisition Corp. (until Jul 19, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | $21.3M |
| Operating income | -$61.3M | -$38.4M | -$192.3M | -$25.6M | -$109.1M |
| Net income | -$91.7M | -$57.9M | -$196.3M | $14.2M | -$100.1M |
| Diluted EPS | -$3.59 | -$2.64 | -$11.02 | $0.95 | — |
| Operating cash flow | -$13.3M | -$6.4M | -$38.7M | -$137.9M | -$110.1M |
| Free cash flow | — | -$6.6M | -$39.7M | -$143.1M | -$116.3M |
| Total assets | $107.3M | $132.7M | $143.9M | $401.1M | $414.1M |
| Total liabilities | $145.4M | $123.8M | $102.9M | $202.2M | $314.7M |
| Stockholders' equity | -$38.1M | $8.8M | $41.0M | $198.9M | $99.4M |
| Cash and investments | $6.2M | $738,000 | $227,000 | $14.0M | $37.2M |
| Total debt | $60.7M | $26,548 | $43.4M | $65.6M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Oct 20, 2026 | Jun 30, 2026 |
| 10-K/A | Amended annual report | Oct 20, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Sep 29, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Officer or director change
|
Sep 28, 2026 | Sep 18, 2026 |
All 560 Celularity Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.